We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Intra Cellular Therapies Inc | NASDAQ:ITCI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54 | -0.77% | 69.80 | 64.01 | 69.80 | 71.35 | 68.48 | 71.07 | 909,098 | 23:29:53 |
From May 2019 to May 2024
Intra-Cellular Therapies Inc. said its lead drug candidate had a similar rate of effectiveness to placebo in a Phase 3 schizophrenia trial.
The company's shares fell 65% in after-hours trading to $42.35.
The study of the biopharmaceutical company's ITI-007 treatment, which used risperidone as an active control, had a primary endpoint of change from baseline on the Positive and Negative Syndrome Scale score.
The two ITI-007 doses in the study demonstrated a change from baseline of minus 14.6 points and minus 15 points, compared with minus 15.1 points in placebo and 20.5 in risperidone.
Intra-Cellular said there was "an unusually high placebo response at certain sites which disproportionately affected the trial results."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
September 28, 2016 17:25 ET (21:25 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Intra Cellular Therapies Chart |
1 Month Intra Cellular Therapies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
